Sasanlimab - Pfizer
Alternative Names: PF-06801591; PF-6801591; RN-888Latest Information Update: 17 Jan 2025
Price :
$50 *
At a glance
- Originator Pfizer
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Bladder cancer
- Phase II Renal cell carcinoma
- Phase I/II Non-small cell lung cancer; Solid tumours
- Discontinued Lymphoma
Most Recent Events
- 10 Jan 2025 Efficacy and adverse event data from phase III CREST trial for Bladder cancer released by Pfizer
- 06 Nov 2024 Pfizer terminates phase-I clinical trials in Solid tumours (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Puerto Rico, USA (SC) (NCT06448364)
- 01 Nov 2024 Pfizer initiates enrolment in a phase I trial for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in USA (SC, Injection) (NCT06580938)